O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation
暂无分享,去创建一个
Simone Kreth | Niklas Thon | H. Kretzschmar | L. C. Hinske | S. Kreth | F. Kreth | J. Tonn | Sabina Eigenbrod | R. Egensperger | Rupert Egensperger | N. Thon | S. Eigenbrod | J. Lutz | C. Ledderose | Hans A. Kretzschmar | Friedrich W. Kreth | Carola Ledderose | Joerg C. Tonn | Juergen Lutz | Ludwig C. Hinske | Carola Ledderose
[1] G. Reifenberger,et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas , 2007, International journal of cancer.
[2] E L Kaplan. NON-PARAMETRIC ESTIMATION FROM INCOMPLETE OBSERVATION , 1958 .
[3] M. Christmann,et al. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. , 2007, DNA repair.
[4] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[5] I. Bièche,et al. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] J. Minna,et al. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14ARF, p16INK4a and RASSF1A in human lung cancer cell lines , 2002, Oncogene.
[7] K. Robertson,et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. , 1999, Nucleic acids research.
[8] H. Kretzschmar,et al. Identification of valid endogenous control genes for determining gene expression in human glioma. , 2010, Neuro-oncology.
[9] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] H. Heinzl,et al. Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.
[11] C. Sommer,et al. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma , 2010, International journal of cancer.
[12] H. Kretzschmar,et al. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[13] Chih-Yi Chen,et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. , 2010, The Journal of clinical investigation.
[14] J. Mehrkens,et al. Novel Molecular Stereotactic Biopsy Procedures Reveal Intratumoral Homogeneity of Loss of Heterozygosity of 1p/19q and TP53 Mutations in World Health Organization Grade II Gliomas , 2009, Journal of neuropathology and experimental neurology.
[15] F. Zanella,et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.
[16] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[17] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[18] M. Wolter,et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors , 2005, International journal of cancer.
[19] T. Siegal,et al. Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. , 2007, Cancer research.
[20] Shinya Tanaka,et al. Careful Exclusion of Non-neoplastic Brain Components is Required for an Appropriate Evaluation of O6-methylguanine-DNA Methyltransferase Status in Glioma: Relationship Between Immunohistochemistry and Methylation Analysis , 2008, The American journal of surgical pathology.
[21] P. Kleihues,et al. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.
[22] V. Beneš,et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.
[23] G. Reifenberger,et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.
[25] K. Hoang-Xuan,et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. , 2009, Neuro-oncology.
[26] Y. Shim,et al. Elevated mRNA levels of DNA methyltransferase‐1 as an independent prognostic factor in primary nonsmall cell lung cancer , 2006, Cancer.
[27] A. Brandes,et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[29] D. Karnofsky. The clinical evaluation of chemotherapeutic agents in cancer , 1949 .
[30] S. Hirohashi,et al. Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues , 2006, International journal of cancer.
[31] S. Spiegl-Kreinecker,et al. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. , 2010, Neuro-oncology.
[32] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[33] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[34] A. von Deimling,et al. RASSF1A, BLU, NORE1A, PTEN and MGMT Expression and Promoter Methylation in Gliomas and Glioma Cell Lines and Evidence of Deregulated Expression of de novo DNMTs , 2009, Brain pathology.
[35] T. Ushijima,et al. Detection and interpretation of altered methylation patterns in cancer cells , 2005, Nature Reviews Cancer.
[36] Colin M. MacLeod,et al. Evaluation of chemotherapeutic agents , 1949 .